Cargando…
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
SUMMARY: Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term tre...
Autores principales: | Meunier, P. J., Roux, C., Ortolani, S., Diaz-Curiel, M., Compston, J., Marquis, P., Cormier, C., Isaia, G., Badurski, J., Wark, J. D., Collette, J., Reginster, J. Y. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744775/ https://www.ncbi.nlm.nih.gov/pubmed/19153678 http://dx.doi.org/10.1007/s00198-008-0825-6 |
Ejemplares similares
-
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
por: Reginster, J-Y., et al.
Publicado: (2011) -
Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis
por: Roux, C, et al.
Publicado: (2008) -
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover
por: Collette, J., et al.
Publicado: (2009) -
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis
por: Hiligsmann, M., et al.
Publicado: (2013) -
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
por: Cesareo, Roberto, et al.
Publicado: (2010)